Patent ID: 9284530
Filing Date: 2016-03-15
CPC Classification: C12N

Claim Text:
1. A method for reconstituting a recipient host with a population of hematopoietic stem cells (HSCs) generated in vivo, the method comprising: administering to the recipient host a pharmaceutical composition comprising an antagonist that reduces the expression and/or the activity of latexin, wherein the recipient host is affected with at least one condition selected from the group consisting of: a disease of the bone marrow, a cancer of the blood, a cancer of the bone marrow, an immunological disorder, thalassemia major, sickle-cell disease, and myelodysplastic syndrome, wherein the antagonist can promote HSC proliferation by at least 25%, wherein latexin includes a latexin polynucleotide variant and/or a latexin polypeptide variant that interacts with the antagonist, and wherein the latexin polynucleotide variant has at least 95% sequence identity to the full length of SEQ ID NO: 1 and the latexin polypeptide variant has 100% sequence identity to the full length of SEQ ID NO: 2.